在晚期非小细胞肺癌的抗PD1治疗期间,与伪进展和超进展性疾病相关的基因组变化
Rui Zhou1,2, Fan Tong1,2, Yongchang Zhang3
1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in oncology
|November 29, 2023
概括
使用下一代测序 (NGS) 进行动态基因组突变监测,可以在接受免疫治疗的高级非小细胞肺癌 (NSCLC) 患者中区分伪进展 (PsPD) 和超进展性疾病 (HPD).
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 将伪进展 (PsPD) 与超进展性疾病 (HPD) 区分开来,对于高级非小细胞肺癌 (NSCLC) 的有效免疫疗法至关重要.
- 接受抗PD1治疗的患者的动态基因组变化需要进一步调查,以了解它们在治疗反应和进展模式中的作用.
研究的目的:
- 调查动态基因组突变变化与在接受抗PD1免疫治疗的晚期NSCLC患者中发展PsPD或HPD之间的关系.
- 通过基因组分析建立区分PSPD与HPD的临床证据.
主要方法:
- 接受抗PD1疗法治疗的高级NSCLC患者被纳入.
- 在基线和图像进展后收集全血样.
- 血清接受了425个面板下一代测序 (NGS) 进行基因组突变分析.
主要成果:
- 在治疗前,NGS确定了与PsPD和HPD相关的独特基因突变配置文件.
- 动态监测揭示了治疗后全血基因组突变谱的显著变异.
- 在图像进展后,在HPD组中观察到突变负荷,等位基因频率和循环瘤DNA的更高折变化.
结论:
- 通过NGS进行动态全基因组突变分析,比单基因检测更有效地区分PSPD和HPD.
- 进展后的基因组变化表明HPD患者的真正疾病进展.
- 这种方法为指导NSCLC临床免疫疗法决策提供了一种新的方法.
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K